Brief: Mesoblast Partners With Blood And Marrow Transplant Clinical Trials Network
22/11/2023 01:29
Nov 22 (Reuters) - Mesoblast Ltd MSB.AX :
* PARTNERS WITH BLOOD AND MARROW TRANSPLANT CLINICAL TRIALS
NETWORK (BMT CTN)
* AGREEMENT TO DEVELOP A PIVOTAL TRIAL OF CO'S LEAD PRODUCT
CANDIDATE RYONCIL
Source text for Eikon: ID:nASX8wYnYX
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M